NASDAQ:MLNT - Melinta Therapeutics Stock Price, News, & Analysis

Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."

Shares of Melinta Therapeutics reverse split on the morning of Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 21st 2019. An investor that had 100 shares of Melinta Therapeutics stock prior to the reverse split would have 20 shares after the split.

Melinta Therapeutics Inc (NASDAQ:MLNT) released its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($6.90) EPS for the quarter, missing analysts' consensus estimates of ($5.70) by $1.20. The biotechnology company had revenue of $12.02 million for the quarter, compared to analyst estimates of $12.06 million. Melinta Therapeutics had a negative net margin of 202.31% and a negative return on equity of 68.68%. View Melinta Therapeutics' Earnings History.

Melinta Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Melinta Therapeutics.

7 Wall Street analysts have issued 12 month price targets for Melinta Therapeutics' shares. Their forecasts range from $40.00 to $75.00. On average, they expect Melinta Therapeutics' share price to reach $62.9167 in the next year. This suggests a possible upside of 1,124.1% from the stock's current price. View Analyst Price Targets for Melinta Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Melinta Therapeutics.

Headlines about MLNT stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Melinta Therapeutics earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future.

Melinta Therapeutics saw a increase in short interest in the month of February. As of February 15th, there was short interest totalling 2,245,682 shares, an increase of 90.6% from the January 31st total of 1,178,376 shares. Based on an average daily volume of 3,554,089 shares, the short-interest ratio is presently 0.6 days. Currently, 31.2% of the company's shares are short sold. View Melinta Therapeutics' Current Options Chain.

Some companies that are related to Melinta Therapeutics include BioTime (BTX), BELLUS Health (BLU), ProMetic Life Sciences (PLI), MediGene (MDG1), Bioventix (BVXP), IMV (IMV), BELLUS Health (BLUSF), OncoCyte (OCX), CorMedix (CRMD), CorMedix (CRMD), Rafael (RFL), Arix Bioscience (ARIX), Cynata Therapeutics (CYP), Millendo Therapeutics (MLND) and Aerpio Pharmaceuticals (ARPO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Melinta Therapeutics investors own include Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), Celgene (CELG), Dynavax Technologies (DVAX), Novavax (NVAX), Inovio Pharmaceuticals (INO), Portola Pharmaceuticals (PTLA), TransEnterix (TRXC), Micron Technology (MU) and NVIDIA (NVDA).

Melinta Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.52%), First Manhattan Co. (1.69%), Dimensional Fund Advisors LP (1.38%), Dimensional Fund Advisors LP (6.90%), Millennium Management LLC (1.07%) and Fosun International Ltd (0.88%). Company insiders that own Melinta Therapeutics stock include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics.

MLNT stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co. and Millennium Management LLC. View Insider Buying and Selling for Melinta Therapeutics.

MLNT stock was purchased by a variety of institutional investors in the last quarter, including Fosun International Ltd, Two Sigma Investments LP, Assenagon Asset Management S.A., Boenning & Scattergood Inc., BlackRock Inc., Condor Capital Management, Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. Company insiders that have bought Melinta Therapeutics stock in the last two years include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Insider Buying and Selling for Melinta Therapeutics.

Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MLNT stock can currently be purchased for approximately $5.14.

Melinta Therapeutics has a market capitalization of $57.59 million and generates $33.86 million in revenue each year. The biotechnology company earns $-58,910,000.00 in net income (profit) each year or ($109.30) on an earnings per share basis. Melinta Therapeutics employs 290 workers across the globe.

The official website for Melinta Therapeutics is http://melinta.com.

Melinta Therapeutics' mailing address is 300 GEORGE STREET SUITE 301, NEW HAVEN CT, 06511. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected]